E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK

Key Points

• E. Ohman J or Asset Management AB cut its stake in Scholar Rock by 76.6% in Q4, selling 53,513 shares and ending the period with 16,374 shares worth $721,000.
• Institutional investors own 91.08% of SRRK, with major holders including Vanguard (~4.91M shares, ~$183M) and Wellington (~4.55M shares) holding multi‑million share positions.
• Wall Street is broadly positive: the consensus rating is a Buy with an average price target of $54.36, multiple firms recently raised targets (e.g., BMO to $70, Piper to $58), and Scholar Rock slightly beat quarterly EPS estimates ($-0.76 vs. $-0.86).

E. Ohman J or Asset Management AB cut its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,374 shares of the company's stock after selling 53,513 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Scholar Rock were worth $721,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Scholar Rock by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company's stock valued at $183,032,000 after buying an additional 53,333 shares during the period. Wellington Management Group LLP grew its holdings in Scholar Rock by 124.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company's stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the period. Bellevue Group AG grew its holdings in Scholar Rock by 10.1% during the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company's stock worth $120,827,000 after acquiring an additional 297,242 shares during the period. Eventide Asset Management LLC raised its position in shares of Scholar Rock by 9.5% in the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company's stock worth $103,192,000 after acquiring an additional 251,638 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Scholar Rock in the 3rd quarter worth about $91,670,000. Institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Performance

Shares of SRRK opened at $45.43 on Thursday. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The company has a market cap of $5.22 billion, a PE ratio of -13.24 and a beta of 0.70. The stock has a 50-day moving average of $45.15 and a 200-day moving average of $40.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) EPS. On average, equities research analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on SRRK. Cantor Fitzgerald restated an "overweight" rating on shares of Scholar Rock in a research report on Thursday, December 11th. Piper Sandler boosted their price target on Scholar Rock from $51.00 to $58.00 and gave the company an "overweight" rating in a research note on Wednesday, March 4th. BMO Capital Markets increased their price target on Scholar Rock from $50.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an "overweight" rating in a research report on Monday, March 16th. Finally, Truist Financial lifted their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Scholar Rock presently has a consensus rating of "Buy" and an average price target of $54.36.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the sale, the insider owned 98,445 shares in the company, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Caryn Parlavecchio sold 9,035 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $420,398.55. Following the transaction, the insider owned 169,087 shares in the company, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 207,464 shares of company stock worth $9,157,423. Insiders own 13.30% of the company's stock.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.